Daiichi forecasts 3.9% sales drop; Impax posts 11% increase in sales;

@FiercePharma:  Dutch researchers are comparing GSK's Advair Diskus with a rival device in a study funded by $GSK. Item | Follow @FiercePharma

> Daiichi Sankyo shares dropped after the drugmaker lowered its sales forecast for the year ending March 2012, predicting a decline of 3.9% on the stronger yen. Article

> Impax Laboratories ($IPXL) posted street-beating profits of $17.2 million on revenue of $119.8 million, an 11% year-over-year increase. Story

> Contract manufacturer Lonza saw revenue growth suffer during the third quarter, thanks to the strength of the Swiss franc and high raw materials prices. Item

> Lupus organizations are lobbying the U.K.'s National Institute for Health and Clinical Excellence for coverage on the new drug Benlysta from Human Genome Sciences and GlaxoSmithKline ($GSK). Release

> Environmental and parent groups are pushing Johnson & Johnson ($JNJ) to remove potentially harmful chemicals from U.S. versions of its baby shampoo as it has in some other markets. News

Biotech News

@FierceBiotech: PathoGenetix raises $7.5M in second closing of series B financing for rapid bacterial identification system. Story | Follow @FierceBiotech

@JohnCFierce: Exelixis has always had problems with study designs; source of issue with BMS. Fight the FDA, though? Shares tank. Item | Follow @JohnCFierce

@RyanMFierce: U.K. trial aims to test use of agents to make tricky brain tumors glow to aid surgical removal. Makes sense. Report | Follow @RyanMFierce 

> Exelixis clashes with FDA over prostate cancer study, shares tank. Story

> NPS Pharma shares sink after cancers reported in patients on bowel drug. Report

> Report: Biotech VCs from Morgenthaler, ATV part ways with IT colleagues. Item

Biotech Research News

> Jackson Lab ready to start hiring for new genetics center. Item

> Caltech team designs a new and improved HIV antibody. Article

> Court ruling could derail ambitious stem cell program for synthetic blood. Report

> Investigators tout a new therapeutic approach to cardiovascular disease. News

Manufacturing News

> Ranking: Baxter, J&J lead green pharma companies. News

> Researchers tout big increase in heparin yield. Report

> KV Pharma, ex-CEO battle over recall responsibility. Item

> Closures a sign of Novartis minimizing production in Switzerland. Report

> Obama takes aim at drug shortages. News 

And Finally... A significant number of colon cancers could be caused by a bacteria, a new study finds. Article

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.